hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06353672, orgStudyIdInfo id: RLR-01, briefTitle: A Study to Evaluate Safety and Feasibility of Robotic Liver Resection, statusModule overallStatus: RECRUITING, startDateStruct date: 2020-12-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Zhejiang University, class: OTHER, descriptionModule briefSummary: The robotic surgery system, the most advanced technology in minimally invasive surgery, overcame some shortcomings of laparoscopic surgery and improved the flexibility and precision of liver resection. Several studies have demonstrated that the robotic system was safe and feasible in liver surgery and might be advantageous in complex hepatic vein and hilar dissection, operative bleeding control, and biliary reconstruction. Previous comparative studies found limited evidence for significantly improved outcomes in robotic liver resection (RLR) over laparoscopic liver resection (LLR) or open liver resection (OLR), considering the various degrees of difficulty in liver surgeries.This study aimed to evaluate safety and feasibility of robotic liver resection, by comparing it with LLR or OLR, and gain veritable and relevant data on the benefits of RLR., conditionsModule conditions: Liver Diseases, conditions: Surgery, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 1000, type: ESTIMATED, armsInterventionsModule interventions name: Robotic liver resection, outcomesModule primaryOutcomes measure: Postoperative complications, primaryOutcomes measure: Postoperative hospital stay, primaryOutcomes measure: Postoperative unplanned reoperation, primaryOutcomes measure: Unplanned readmission, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: First Affiliated Hospital, Medical College of Zhejiang University, status: RECRUITING, city: Hangzhou, state: Zhejiang, zip: 310003, country: China, contacts name: Tingbo Liang, MD,PHD, role: CONTACT, phone: 086-571-87236688, email: liangtingbo@zju.edu.cn, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06353659, orgStudyIdInfo id: M2024077, briefTitle: The Diagnostic Value of Contrast-enhanced Ultrasound in Acute Kidney Injury in ICU, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2025-06-30, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Peking University Third Hospital, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to quantitatively assess the renal microcirculation changes by contrast-enhanced ultrasound (CEUS) and to obtain systemic hemodynamic information by ultrasound Doppler at the same time, to analyze the relationship between renal microcirculation changes and systemic hemodynamic changes, and to explore the diagnostic value of CEUS in critically ill acute kidney injury., conditionsModule conditions: Intensive Care Unit, conditions: Acute Kidney Injury, conditions: Ultrasound, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Contrast-enhanced Ultrasound, outcomesModule primaryOutcomes measure: Acute kidney injury (according to KDIGO 2012 criteria), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06353646, orgStudyIdInfo id: XKY-C-004, briefTitle: XH001 Combination With Ipilimumab and Chemotherapy for Patients With Resected Pancreatic Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-06, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Wu Wenming, class: OTHER, collaborators name: NeoCura, descriptionModule briefSummary: This is a single-center, open label, single-arm, investigator-initiated study to evaluate the efficacy and safety of XH001 (neoantigen cancer vaccine) sequential combination with ipilimumab and chemotherapy in pancreatic cancer patients following surgical resection., conditionsModule conditions: Pancreatic Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: XH001, interventions name: Ipilimumab Injection, interventions name: Chemotherapy, outcomesModule primaryOutcomes measure: DFS, primaryOutcomes measure: 1-year DFS rate, primaryOutcomes measure: MFS, primaryOutcomes measure: OS, secondaryOutcomes measure: Elispot, secondaryOutcomes measure: Adverse Event, secondaryOutcomes measure: ctDNA, secondaryOutcomes measure: CA19-9, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking Union Medical College Hospital, city: Beijing, state: Beijing, zip: 100730, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06353633, orgStudyIdInfo id: AHekmatdoost, briefTitle: The Effect of Exclusion Diet for Crohn's Disease Plus Enteral Nutrition on Children and Adolescents With Crohn's Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-10, primaryCompletionDateStruct date: 2024-10-20, completionDateStruct date: 2024-12-25, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: National Nutrition and Food Technology Institute, class: OTHER, descriptionModule briefSummary: In this study, children and adolescents with active Crohn's disease are placed in two intervention groups, the first group receives only an exclusion diet and the second group receives an exclusion diet plus formula., conditionsModule conditions: Inflammatory Bowel Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 44, type: ESTIMATED, armsInterventionsModule interventions name: formula, interventions name: exclusion diet, outcomesModule primaryOutcomes measure: PCDAI, primaryOutcomes measure: CRP, primaryOutcomes measure: ESR, primaryOutcomes measure: FC, primaryOutcomes measure: Alb, secondaryOutcomes measure: Arm Circumferance, secondaryOutcomes measure: BMI, secondaryOutcomes measure: Height, secondaryOutcomes measure: weight, eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06353620, orgStudyIdInfo id: 1018, briefTitle: Structural-functional Connectome in Drug-resistant Epilepsies and Neurodevelopmental Syndromes With Epilepsy, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-13, primaryCompletionDateStruct date: 2024-03-18, completionDateStruct date: 2027-02-28, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: IRCCS Eugenio Medea, class: OTHER, descriptionModule briefSummary: Recent studies have shown that the aperiodic part of the signal (neuronal avalanches) of electroencephalography (EEG) contains important information about the dynamics of neuronal networks. Indeed, this has helped to identify functionally altered areas in patients with temporal epilepsy by simply using the resting EEG signal. Furthermore, it has been seen that the propagation of neuronal avalanches (VNs) correlates with the morphological organization of the cerebral cortex. Therefore, NAs represent a measure with direct utility for studying functional reorganization pre and post drug/surgical treatment. In addition, the aperiodic portion of the signal may represent a noninvasive measure of the excitation/inhibition relationship, which is known of being altered both in epilepsy and in some rare neurodevelopmental syndromes (example: Angelman and Dup15q), conditionsModule conditions: Epilepsy, conditions: Angelman Syndrome, conditions: Dup15q Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: High Density EEG recording, interventions name: Rey Complex Figure Test, outcomesModule primaryOutcomes measure: Differences in the network coherence values in theta and alpha band after treatment, primaryOutcomes measure: Stability of the alpha frequency band in the EEG activity, primaryOutcomes measure: Correlation of neural excitation and memory performance, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 75 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: IRCCS E.Medea, status: RECRUITING, city: Conegliano, state: Treviso, zip: 31015, country: Italy, contacts name: Duma Gian Marco, PhD, role: CONTACT, phone: +39 0438414248, email: gianmarco.duma@lanostrafamiglia.it, geoPoint lat: 45.88805, lon: 12.30201, hasResults: False
protocolSection identificationModule nctId: NCT06353607, orgStudyIdInfo id: 2023-02267; kt23Berdajs, briefTitle: Genetic Architecture of Acute Aortic Syndromes and Aortic Aneurysm., statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-08, primaryCompletionDateStruct date: 2028-12-31, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: University Hospital, Basel, Switzerland, class: OTHER, descriptionModule briefSummary: The aim of this study is to explore the genetic information associated with the development of TAA and aAD in individuals without history or syndromic features (Marfan syndrome, Ehlers-Danlos syndrome, Turner syndrome etc.) for aortic disease. For this purpose, whole genome sequencing will be performed in patients with documented aortic aneurysm or/and aortic dissection., conditionsModule conditions: Acute Aortic Dissection, conditions: Thoracic Aortic Aneurysm, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 730, type: ESTIMATED, outcomesModule primaryOutcomes measure: Assessment of the association between the prevalence of TAA and/or aAD in variants with genes associated with thoracic aortic disease., secondaryOutcomes measure: Investigate the genetic landscape of aortic specimens retrieved from surgical intervention tissues, and relate the genetic profile to cell molecular pathology., secondaryOutcomes measure: To assess the association between the aortic segment dimension (in CT scan and TEE images), tissue pathology and gene variants to determine the images predictive factors for TAA and/or aAD., secondaryOutcomes measure: To establish a risk prediction model for aAD and TAA based on genetic, clinical, and imaging endpoints., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University Hospital Basel, status: RECRUITING, city: Basel, zip: 4031, country: Switzerland, contacts name: Denis Berdajs, Prof. Dr., role: CONTACT, phone: 0041 61 328 71 80, email: denis.berdajs@usb.ch, contacts name: Islam Salikhanov, Dr., role: CONTACT, phone: 0041 61 26 53225, email: islam.salikhanov@usb.ch, geoPoint lat: 47.55839, lon: 7.57327, hasResults: False
protocolSection identificationModule nctId: NCT06353529, orgStudyIdInfo id: 17065, briefTitle: Sphenopalatine Ganglion Block for Postop Pain Management, acronym: SPGB, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Hamilton Health Sciences Corporation, class: OTHER, descriptionModule briefSummary: To assess the benefit of using an additional nerve block during minimally invasive pituitary surgery, to improve pain management after surgery. The medication (Bupivacaine) or a placebo (saline) will be injected during surgery and patients will be asked about their level of pain at multiple time points in the first 24 hours following surgery. The aim is to improve patient outcomes and reduce the need for pain medication after surgery., conditionsModule conditions: Pituitary, conditions: Pain, Postoperative, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 52, type: ESTIMATED, armsInterventionsModule interventions name: Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution, interventions name: Placebo, outcomesModule primaryOutcomes measure: Post-operative pain score, secondaryOutcomes measure: Post-operative bleeding, secondaryOutcomes measure: Post-operative complications, secondaryOutcomes measure: Analgesic requirement, secondaryOutcomes measure: Length of stay, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hamilton General Hospital, city: Hamilton, state: Ontario, zip: L8L 2X2, country: Canada, contacts name: Dr. Kesava Reddy, MD, role: CONTACT, phone: 905-521-2100, email: reddy@hhsc.ca, contacts name: Ms. Jessy Moore, MSc, role: CONTACT, phone: 289-686-8827, email: moorej@hhsc.ca, geoPoint lat: 43.25011, lon: -79.84963, hasResults: False
protocolSection identificationModule nctId: NCT06353516, orgStudyIdInfo id: 2310-117-126, briefTitle: The Effect of Intravenous Versus Volatile Anesthesia on Postoperative Cognitive Dysfunction in Elderly Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-14, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Chung-Ang University Gwangmyeong Hospital, class: OTHER, collaborators name: National Research Foundation of Korea, descriptionModule briefSummary: The goal of this clinical trial is to compare the permeability of blood-brain barrier between the intravenous anesthesia group and the inhalation gas anesthesia group in the elderly patients undergoing surgery. The main questions it aims to answer are:* \[Is the permeability of blood-brain barrier between the intravenous anesthesia group and the inhalation gas anesthesia group in the elderly patients different?\]* \[Is the incidence of postoperative cognitive dysfunction between the intravenous anesthesia group and the inhalation gas anesthesia group different?\] Participants will be anesthetized with different categories of anesthetics.  * Intravenous anesthetics  * Inhalation gas anesthetics, conditionsModule conditions: Postoperative Cognitive Dysfunction, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The participants are randomly assigned to total intravenous anesthesia group or inhaled gas anesthesia group, primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, maskingDescription: This study is a double-blinded randomized controlled trial. The group assignment is conducted by the pre-generated random number table. The participant, investigator and the outcome assessor are blinded to the group assignment., whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 154, type: ESTIMATED, armsInterventionsModule interventions name: Propofol, interventions name: Sevoflurane, outcomesModule primaryOutcomes measure: Concentration of serum S100B levels, secondaryOutcomes measure: Incidence of Delirium, secondaryOutcomes measure: Incidence of Postoperative Cognitive Dysfunction, secondaryOutcomes measure: Concentration of serum albumin, secondaryOutcomes measure: Concentration of serum CRP, secondaryOutcomes measure: Concentration of serum IL6 levels, secondaryOutcomes measure: Concentration of serum TNFα levels, secondaryOutcomes measure: Concentration of cerebrospinal fluid (CSF) albumin, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Chung-Ang University Gwangmyeong Hospital, status: RECRUITING, city: Gwangmyeong, state: Gyeonggi-do, zip: 14353, country: Korea, Republic of, contacts name: Wongook Wi, M.D., role: CONTACT, phone: 02-2222-1553, email: hestia.w@gmail.com, hasResults: False
protocolSection identificationModule nctId: NCT06353503, orgStudyIdInfo id: KAZ, briefTitle: Bone Marrow Aspirate Concentrate for Anterior Cruciate Ligament Tear Treatment., statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-02, primaryCompletionDateStruct date: 2024-09-27, completionDateStruct date: 2024-09-27, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: abdulmajeed hammadi, class: INDUSTRY, descriptionModule briefSummary: A single armed multicenter study enrolling 20 patients using autologous bone marrow aspirate concentrate (which is done under local or general anesthesia to aspirate around 1-2 cc/kg body weight then concentration which is done by using centrifugation and special disposable kit) local injection of 4 cc per joint under ultrasonic guidance ,completely sterile field with local anesthesia., conditionsModule conditions: Anterior Cruciate Ligament Tear, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: single armed study open label, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: autologous bone marrow aspirate concentrate, outcomesModule primaryOutcomes measure: Functional recovery by clinical assessments of the ACL and overall knee joint stability., secondaryOutcomes measure: magnetic resonance imaging of the knee joint, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Ministry of Health, status: RECRUITING, city: Baghdad, zip: 964, country: Iraq, contacts name: thamer A alrubaie, MD, role: CONTACT, phone: +9647700009294, email: alzaitounhospital@gmail.com, geoPoint lat: 33.34058, lon: 44.40088, hasResults: False
protocolSection identificationModule nctId: NCT06353490, orgStudyIdInfo id: Geon-111001, briefTitle: The Clinical Performance Validation of Electronic Thermometer and Infrared Thermometers, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-08-12, primaryCompletionDateStruct date: 2023-11-08, completionDateStruct date: 2024-08-11, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Geon Corporation, class: INDUSTRY, descriptionModule briefSummary: Geon Corporation develops ear thermometers and forehead thermometers that use infrared measurement technology to measure human body temperature. This study verify the accuracy and repeatability of investigational devices. Efficacy verification is carried out by comparing with the referent medical devices.The main objectives of this study are:1. To verify that the investigational devices and the reference medical devices have a reasonable deviation value.2. To verify the consistency of repeated measurements of investigational devices., conditionsModule conditions: Febrile, conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ACTUAL, armsInterventionsModule interventions name: Infrared Forehead Thermometer (GE-TF03), interventions name: Infrared Ear Thermometer (GE-TE06), interventions name: Electronic Thermometer (MT-B321FB), interventions name: Electronic Thermometer (MT-B231), outcomesModule primaryOutcomes measure: Clinical Bias, primaryOutcomes measure: Limits of Agreement, primaryOutcomes measure: Clinical Repeatability, eligibilityModule sex: ALL, maximumAge: 80 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hsinchu MacKay Memorial Hospital, city: Hsinchu, country: Taiwan, geoPoint lat: 24.80361, lon: 120.96861, locations facility: HsinChu Municipal MacKay Memorial Hospital, city: Hsinchu, country: Taiwan, geoPoint lat: 24.80361, lon: 120.96861, hasResults: False